{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:36Z","timestamp":1793943756747,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103084","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:11:41Z","timestamp":1788390701000},"page":"103084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption"],"prefix":"10.1016","volume":"37","author":[{"given":"Marta","family":"Losa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Rajmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Stanaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Coons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhavi","family":"Garish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Churchward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur L.G.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Donohoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gradia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghdad","family":"Rahdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7790-4307","authenticated-orcid":false,"given":"Steven B.","family":"Kanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103084_bib1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103084_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103084_bib3","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.103084_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"van Haasteren","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103084_bib7","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR\u2013Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib8","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103084_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/v11010028","article-title":"Viral Delivery Systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2026.103084_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103084_bib11","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103084_bib12","article-title":"Unsaturated, trialkyl ionizable lipids are versatile LNP components for therapeutic and vaccine applications","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2026.103084_bib13","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omtn.2026.103084_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2026.103084_bib15","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1073\/pnas.1520244113","article-title":"Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103084_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient CRISPR\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2026.103084_bib17","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omtn.2026.103084_bib18","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR-Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2026.103084_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"Crispr-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103084_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of Klkb1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103084_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2020.12.013","article-title":"Lipid nanoparticles loaded with ribonucleoprotein\u2212oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition","volume":"330","author":"Suzuki","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103084_bib22","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103084_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103084_bib24","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.103084_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","article-title":"Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR\u2212Cas gene editing","volume":"20","author":"Liu","year":"2021","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omtn.2026.103084_bib26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid Nanoparticles for mRNA Delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2026.103084_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103084_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","volume":"3","author":"Xu","year":"2023","journal-title":"ACS Nano. Au"},{"key":"10.1016\/j.omtn.2026.103084_bib29","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2212Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.103084_bib31","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1021\/bm700753q","article-title":"Steric stabilization of lipid\/polymer particle assemblies by poly(ethylene glycol)-lipids","volume":"8","author":"Th\u00e9venot","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.omtn.2026.103084_bib32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0006-3495(01)76202-9","article-title":"Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes","volume":"80","author":"Maurer","year":"2001","journal-title":"Biophys. J."},{"key":"10.1016\/j.omtn.2026.103084_bib33","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib34","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib35","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2212Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2026.103084_bib38","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/s41467-023-42948-2","article-title":"Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib39","doi-asserted-by":"crossref","first-page":"21321","DOI":"10.1021\/jacs.1c09822","article-title":"Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2026.103084_bib40","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103084_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.103084_bib42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","article-title":"Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry","volume":"23","author":"Li","year":"2024","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omtn.2026.103084_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2026.103084_bib44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2021.11.022","article-title":"Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery","volume":"341","author":"Melamed","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103084_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells","volume":"33","author":"Hendel","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib47","doi-asserted-by":"crossref","first-page":"E7110","DOI":"10.1073\/pnas.1520883112","article-title":"Synthetic CRISPR RNA-Cas9-guided genome editing in human cells","volume":"112","author":"Rahdar","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103084_bib48","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1016\/j.molcel.2021.07.035","article-title":"Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells","volume":"81","author":"Donohoue","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2026.103084_bib49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","article-title":"Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness","volume":"25","author":"Lau","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtn.2026.103084_bib50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","article-title":"High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR-T cells suppresses allograft rejection in preclinical models","volume":"12","author":"Degagn\u00e9","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2026.103084_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202201695","article-title":"Understanding intracellular biology to improve mRNA delivery by lipid nanoparticles","volume":"7","author":"Hunter","year":"2023","journal-title":"Small Methods"},{"key":"10.1016\/j.omtn.2026.103084_bib52","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ymthe.2018.02.031","article-title":"Chemically modified Cpf1-CRISPR RNAs mediate efficient genome editing in mammalian cells","volume":"26","author":"McMahon","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103084_bib53","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103084_bib55","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103084_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103084_bib57","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103084_bib58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103084_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41541-024-00835-x","article-title":"Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines","volume":"9","author":"Bae","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omtn.2026.103084_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2026.103084_bib61","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.103084_bib62","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/acsptsci.3c00185","article-title":"Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery","volume":"6","author":"Pozzi","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.omtn.2026.103084_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2004.12.137","article-title":"The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse","volume":"328","author":"Yan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2026.103084_bib64","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2026.103084_bib65","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nbt.3481","article-title":"Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA","volume":"34","author":"Richardson","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103084_bib67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103084_bib68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103084_bib69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103084_bib70","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","article-title":"Treatment of a metabolic liver disease in mice with a transient prime editing approach","volume":"9","author":"Rothgangl","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2026.103084_bib71","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1083\/jcb.201903090","article-title":"The cell biology of the hepatocyte: a membrane trafficking machine","volume":"218","author":"Schulze","year":"2019","journal-title":"J. Cell Biol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:00Z","timestamp":1793632620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002556"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103084","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103084"}}